|
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
|
|
T2 Biosystems Announces First Quarter 2024 Financial Results
|
|
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
|
|
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity
|
|
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
|
|
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
|
|
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
|
|
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
|
|
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
|
|
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
|